Q BioMed Inc. (QBIO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -3.44 Million USD | 53.37% |
| 2021 | -7.38 Million USD | 43.79% |
| 2020 | -13.14 Million USD | -63.91% |
| 2019 | -8.01 Million USD | 11.08% |
| 2018 | -9.01 Million USD | 27.09% |
| 2017 | -12.37 Million USD | -94.94% |
| 2016 | -6.34 Million USD | -566.55% |
| 2015 | -952.13 Thousand USD | -2402.33% |
| 2014 | -38.05 Thousand USD | -7510.0% |
| 2013 | -500.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q2 | - USD | 100.0% |
| 2023 Q1 | -445.01 Thousand USD | -117.24% |
| 2022 Q1 | -1.16 Million USD | 28.22% |
| 2022 Q3 | -781.08 Thousand USD | 16.42% |
| 2022 Q4 | 2.58 Million USD | 430.55% |
| 2022 FY | -3.44 Million USD | 53.37% |
| 2022 Q2 | -934.48 Thousand USD | 19.75% |
| 2021 Q3 | -1.6 Million USD | 11.64% |
| 2021 Q1 | -2.35 Million USD | 31.36% |
| 2021 Q4 | -1.62 Million USD | -1.27% |
| 2021 Q2 | -1.81 Million USD | 22.9% |
| 2021 FY | -7.38 Million USD | 43.79% |
| 2020 FY | -13.14 Million USD | -63.91% |
| 2020 Q4 | -3.42 Million USD | -52.32% |
| 2020 Q1 | -5.83 Million USD | -200.6% |
| 2020 Q2 | -1.63 Million USD | 71.91% |
| 2020 Q3 | -2.24 Million USD | -37.27% |
| 2019 Q2 | -2.26 Million USD | -10.2% |
| 2019 Q1 | -2.05 Million USD | -11.38% |
| 2019 FY | -8.01 Million USD | 11.08% |
| 2019 Q4 | -1.94 Million USD | -10.56% |
| 2019 Q3 | -1.75 Million USD | 22.59% |
| 2018 Q3 | -2.98 Million USD | -48.33% |
| 2018 Q4 | -1.84 Million USD | 38.13% |
| 2018 FY | -9.01 Million USD | 27.09% |
| 2018 Q1 | -2.17 Million USD | 45.0% |
| 2018 Q2 | -2.01 Million USD | 7.42% |
| 2017 Q4 | -3.95 Million USD | -5.81% |
| 2017 FY | -12.37 Million USD | -94.94% |
| 2017 Q3 | -3.73 Million USD | -38.86% |
| 2017 Q2 | -2.69 Million USD | -35.03% |
| 2017 Q1 | -1.99 Million USD | 2.57% |
| 2016 Q2 | -776.04 Thousand USD | 59.81% |
| 2016 Q1 | -1.93 Million USD | -112.93% |
| 2016 FY | -6.34 Million USD | -566.55% |
| 2016 Q4 | -2.04 Million USD | -28.29% |
| 2016 Q3 | -1.59 Million USD | -105.42% |
| 2015 Q3 | -33.2 Thousand USD | -774.2% |
| 2015 Q2 | -3798.00 USD | 53.59% |
| 2015 Q1 | -8184.00 USD | 58.02% |
| 2015 FY | -952.13 Thousand USD | -2402.33% |
| 2015 Q4 | -906.95 Thousand USD | -2631.62% |
| 2014 FY | -38.05 Thousand USD | -7510.0% |
| 2014 Q4 | -19.49 Thousand USD | -218.62% |
| 2014 Q3 | -6118.00 USD | -33.9% |
| 2014 Q1 | -7869.00 USD | 0.0% |
| 2014 Q2 | -4569.00 USD | 41.94% |
| 2013 FY | -500.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.16 Million USD | -8.754% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -269.947% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -31.136% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 80.694% |
| GB Sciences, Inc. | -1.42 Million USD | -142.562% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -1.193% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1465.634% |
| Skye Bioscience, Inc. | -13.67 Million USD | 74.798% |
| Zenith Capital Corp. | -8.94 Million USD | 61.471% |
| Agentix Corp. | -1.37 Million USD | -151.183% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 31.695% |
| Biomind Labs Inc. | -1 Million USD | -241.284% |
| ContraFect Corporation | -56.88 Million USD | 93.943% |
| CSL Limited | 3.7 Billion USD | 100.093% |
| CytoDyn Inc. | -18.05 Million USD | 80.919% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -84.814% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -784.466% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 93.793% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -729.312% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -124.317% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -401.582% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 104.21% |
| SQZ Biotechnologies Company | -75.82 Million USD | 95.456% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -73.453% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 95.2% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -20.877% |
| Mesoblast Limited | -84.14 Million USD | 95.905% |
| Marizyme, Inc. | -34.08 Million USD | 89.892% |
| Genus plc | 6.4 Million USD | 153.838% |
| Pharming Group N.V. | -4.87 Million USD | 29.387% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 58.735% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -145.766% |
| IMV Inc. | -38.67 Million USD | 91.09% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -25.257% |
| MultiCell Technologies, Inc. | -722.81 USD | -476597.334% |
| ONE Bio Corp. | 13.68 Million USD | 125.184% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 94.159% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 197.334% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -18.763% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 48.171% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -11403.793% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 78.288% |
| Alpha Cognition Inc. | -9.7 Million USD | 64.499% |
| Enzolytics Inc. | -2.14 Million USD | -60.351% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.189% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -230.04% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -18.023% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.171% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 170.107% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1216.497% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -40.333% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1908.994% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -71.872% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 135.367% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 24.351% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 8.029% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -250.145% |
| EV Biologics, Inc. | -483.06 Thousand USD | -613.286% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -174.332% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 93.732% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 55.706% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -78.288% |
| HST Global, Inc. | -140.9 Thousand USD | -2345.312% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -158.015% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -206.303% |
| Halberd Corporation | -75.05 Thousand USD | -4491.094% |
| Resverlogix Corp. | -12.74 Million USD | 72.973% |
| Cell Source, Inc. | -4.32 Million USD | 20.339% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -118.166% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 6.69 Million USD | 151.482% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -19678.52% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | -39.682% |
| Kadimastem Ltd | -3.04 Million USD | -13.333% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 18.705% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1798.568% |
| LadRx Corporation | -3.82 Million USD | 9.886% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -401.582% |
| Affymax, Inc. | -15.04 Million USD | 77.099% |
| Itoco Inc. | -919.14 Thousand USD | -274.874% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -207.919% |
| Mobile Lads Corp. | -554.55 Thousand USD | -521.335% |
| International Stem Cell Corporation | -663 Thousand USD | -419.701% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | 9.804% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -13589.376% |
| Qrons Inc. | -643.67 Thousand USD | -435.302% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -510.143% |
| SYBLEU INC | -149.18 Thousand USD | -2209.704% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -54.52% |
| Rebus Holdings, Inc. | -664 Thousand USD | -418.918% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -89.703% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -6445.623% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -16840.098% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 90.499% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -112.955% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -368.259% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -10.756% |
| Neutra Corp. | -229.48 Thousand USD | -1401.449% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 80.355% |
| PureTech Health plc | -146.19 Million USD | 97.643% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 83.967% |
| IXICO plc | -1.43 Million USD | -139.778% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 63.696% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.171% |
| CSL Limited | 3.81 Billion USD | 100.09% |
| Cellectis S.A. | -108.85 Million USD | 96.835% |